Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2255 articles about Gilead Sciences, Inc.
-
Gilead Sciences Publishes 2023 ESG Impact Report
4/18/2024
Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year.
-
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
4/8/2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes.
-
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
4/2/2024
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.
-
Gilead Sciences’ Vemlidy on Thursday secured a label expansion from the FDA, allowing the antiviral drug’s use to treat chronic hepatitis B in pediatric patients aged six years and older.
-
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
3/28/2024
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved the supplemental new drug application for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
3/28/2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
3/22/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.
-
7 Top Companies Hiring Regulatory Jobs
3/14/2024
Looking for regulatory jobs in the biopharma industry? Check out the BioSpace list of seven top companies hiring for these critical roles. -
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
3/11/2024
Gilead Sciences, Inc. announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Gilead’s cash tender offer for CymaBay Therapeutics, Inc. expired at 11:59 p.m. on March 8, 2024.
-
Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing
3/7/2024
For many people living with cancer, hearing about the experiences of others can be helpful.
-
Gilead Sciences is partnering with Dutch biotech Merus to find novel dual tumor-associated antigens that target tri-specific antibodies.
-
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
3/6/2024
Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® for a broad range of people with HIV, including those with HIV/hepatitis B coinfection and HIV/tuberculosis coinfection.
-
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
3/6/2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor.
-
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
3/6/2024
Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
-
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
3/5/2024
Today the Foster City-based company is the second-largest biotech employer in the Bay Area.
-
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
3/5/2024
Gilead Sciences, Inc. announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections.
-
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
3/5/2024
Gilead Sciences, Inc. announced the presentation of key data highlighting the breadth of its innovative HIV treatment research pipeline.
-
Retaining the full rights to Trodelvy, Gilead now has access to $210 million in financing from venture capital firm Abingworth to help push the antibody-drug conjugate into non-small cell lung cancer studies.
-
Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.
2/27/2024
Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States.